Summary
Pneumococcal infections remain a major cause of morbidity and mortality worldwide, especially among children and elderly. Abera Bioscience is developing a novel, universal pneumococcal vaccine (Ab-01.12) using its OMV-based BERA platform. Unlike traditional vaccines, Ab-01.12 is administered nasally and targets all known serotypes through conserved antigens, generating both mucosal and systemic immune responses.
To enable efficient nasal delivery, Abera aims to use Aptar's LuerVax spray device in the planned Phase 1 clinical trial. This project will verify the compatibility of Ab-01.12 with the spray device, ensuring consistent dose delivery and optimal distribution.
Dr Maria Alriksson
CEO
Abera Bioscience AB
Sweden
Collaborators:
Dr Khaled Alzahabi, Formulation Specialist, Nanopharm Ltd, UK
Professor Marien de Jonge, Professor and Head of Laboratory of Medical Immunology, Radboud University Nijmegen and Radboud University Medical College, Netherlands